Clinical Trials Logo

BK Virus Nephropathy clinical trials

View clinical trials related to BK Virus Nephropathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00138424 Terminated - Clinical trials for BK Virus (Nephropathy)

Cidofovir in Renal Transplant Recipients With BKVN

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study will look at the safety, tolerability and effectiveness of cidofovir in kidney transplant patients who have been diagnosed with BK virus nephropathy (BKVN), a viral condition that can cause patients to reject transplanted kidneys. Up to 48 adult (age 18 years and older) kidney or pancreas transplant recipients with newly diagnosed BKVN will receive 1 of 3 cidofovir dose levels or placebo (non medicated substance) to identify the maximum tolerated dose. Dosing will be administered intravenously (by a tube running into a blood vessel). In addition to the screening visit, volunteers will actively participate for approximately 8-10 weeks with a single follow up phone call at 4 months. Blood samples, urine samples, eye exams and physical exams are included in study procedures.